Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Flerie Invest AB is a life science investment firm founded in 2011 by Thomas Eldered, who previously co-founded Recipharm, a leading global drug contract manufacturer. The firm operates from offices in Stockholm and London, managing a portfolio of 25 companies across Europe, Israel, and the United States. As a publicly traded company listed on Nasdaq Stockholm under the ticker FLERIE, Flerie emphasizes transparency and active engagement with its portfolio companies. The firm has raised SEK 832 million (approximately $77 million) through an oversubscribed reverse merger IPO in June 2024, marking a significant milestone as Sweden's first life science IPO in over three years.
Flerie manages over SEK 2,500 million in assets under management (AUM) and has a historical internal rate of return (IRR) of 14.2% per annum from 2011 to 2023. The firm focuses on supporting companies built on pioneering science, providing not only capital but also strategic guidance and operational expertise to enhance growth potential. Flerie's commitment to the life sciences sector is evident in its investment strategy, which spans early-stage product development through to commercial growth.
Flerie primarily invests in the drug development sector, which includes cell and gene therapy, vaccines, biologics, and small molecules. Their investment strategy encompasses both private and selective public companies, as well as investment funds as a limited partner. The firm engages in product development from the formation and pre-clinical stages to clinical phases I, II, and III, supporting companies as they move towards profitability. Flerie looks for companies that are built on pioneering science and have the potential for significant impact in the healthcare sector.
The firm operates globally, with a geographic focus on Europe, Israel, and the United States. Flerie’s investment stages range from pre-seed to Series C, allowing them to support startups at various points in their development. They emphasize long-term partnerships with portfolio companies, providing resources and expertise to navigate the complexities of drug development and commercialization.
Flerie's portfolio includes a diverse range of companies in the biotech and healthcare sectors, showcasing their commitment to pioneering science. Notable companies include:
Flerie actively manages these investments, providing strategic guidance and operational support to enhance their growth potential. The firm’s focus on drug development positions it as a key player in the life sciences sector.
Thomas Eldered: Executive Chairman; co-founder of Recipharm, bringing extensive operational credibility in pharma manufacturing.
Ted Fjällman: Chief Executive Officer; leads the firm with a focus on strategic growth and investment management.
Cecilia Stureborg von Schéele: Chief Financial Officer; oversees financial operations and reporting.
José Ochoa: Venture Partner; provides insights and expertise in biotech investments.
Mark Quick: Partner; focuses on identifying and supporting innovative life science companies.
Michaela Gertz: Head of Investor Relations; manages communications with investors and stakeholders.
Paula Andersson: Investor Relations and Operations Manager; supports operational functions and investor engagement.
Carl-Johan Spak: Senior Advisor; offers strategic advice based on extensive industry experience.
Manuela Widmer: Assistant to CEO; provides administrative support to the executive team.
To pitch Flerie, founders should visit their contact page at flerie.com/en/contact/. It is advisable to include a comprehensive business plan, details about the team, and insights into the technology being developed. Flerie prefers pitches that clearly outline the market opportunity and the unique value proposition of the startup.
Response times may vary, but founders can expect to hear back regarding their pitch within a few weeks. Warm introductions are beneficial but not mandatory.
In June 2024, Flerie successfully completed an oversubscribed reverse merger IPO, raising SEK 832 million (~$77 million) and marking a significant milestone as Sweden's first life science IPO in over three years.
Flerie continues to actively manage a portfolio of 25 companies, focusing on pioneering science in the life sciences sector. The firm has been involved in various funding rounds and collaborations, enhancing its presence in the biotech and healthcare markets.
What are Flerie's investment criteria?
Flerie invests in the drug development sector, focusing on biotech and pharmaceutical companies that are built on pioneering science. They look for companies at various stages, from pre-seed to Series C, and emphasize long-term partnerships.
How can I pitch to Flerie?
Founders can pitch to Flerie through their contact page at flerie.com/en/contact/. It is recommended to include a detailed business plan and information about the team and technology.
What makes Flerie different from other investors?
Flerie combines capital investment with strategic guidance and operational expertise, leveraging a network of industry experts to support portfolio companies. Their focus on life sciences and drug development sets them apart.
What is Flerie's geographic focus?
Flerie invests globally, with a particular emphasis on Europe, Israel, and the United States. This broad geographic focus allows them to tap into diverse markets and innovative companies.
What is the typical check size for Flerie's investments?
Flerie invests across various stages, with check sizes typically aligned with the needs of early-stage to growth-stage companies in the biotech and pharmaceutical sectors.
What kind of support does Flerie provide to portfolio companies?
Flerie offers operational support, strategic guidance, and access to a network of industry experts to help portfolio companies navigate the complexities of drug development and commercialization.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.